http://www.medscape.com/viewarticle/837773

Hi Mary it seems Rytary was approved for use on the basis of three trials.

1 for L-Dopa naive patients and 2 for advanced pd.

My friends experiences are that it is hard to get the dosing down pat and several are ready to quit and go back to conventional L-dopa.

Rytary is designed to address "one of the most significant unmet needs for patients living with Parkinson's disease, which is to reduce the amount of time during the day when their symptoms are not adequately controlled," Fred Wilkinson, president and CEO, Impax Laboratories, said in the company news release.